Kovitz Investment Group Partners
URGN icon

Kovitz Investment Group Partners’s UroGen Pharma URGN Stock Holding History

Kovitz Investment Group Partners’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34,802
Closed -$694K – 1268
2025
Q3 		$694K Hold
34,802
– – ﹤0.01% 931
2025
Q2 		$477K Buy
34,802
+3,511
+11% +$33.7K ﹤0.01% 990
2025
Q1 		$346K Hold
31,291
– – ﹤0.01% 1010
2024
Q4 		$333K Hold
31,291
– – ﹤0.01% 1014
2024
Q3 		$397 Buy
+31,291
New +$464K ﹤0.01% 1047

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Kovitz Investment Group Partners's URGN Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 34,802 shares — an estimated $694K sold.

Kovitz Investment Group Partners first reported a position in URGN in Q3 2024 and held it in 5 quarters. The position peaked at $694K in Q3 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 34,802 UroGen Pharma shares in Q4 2025, an estimated $694K.
  • Kovitz Investment Group Partners first reported a position in UroGen Pharma in Q3 2024 and held it in 5 quarters.
  • Kovitz Investment Group Partners's UroGen Pharma position peaked at $694K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.